Shamburg News · 8-K filed Oct 5, 2026, 8:00 AM EDT

Rezolute Reports FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Drug Ersodetug

RZLT · Rezolute, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: high

Rezolute, Inc. announced that the U.S. Food and Drug Administration recommended a pre-BLA meeting as a precursor to submitting a biologics license application for ersodetug in congenital hyperinsulinism, following a preliminary review of Phase 3 sunRIZE trial data. The company stated the sunRIZE study did not meet its primary endpoint, and the FDA explicitly did not opine on approvability. Rezolute said it will evaluate its overall BLA submission strategy after topline results from the Phase 3 upLIFT study in tumor HI, expected this quarter.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-113503.

Written from the filing by Shamburg Markets. Figures are as reported by the company.